These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8862691)

  • 1. Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence.
    Pyörälä K; Steiner G
    Ann Med; 1996 Aug; 28(4):357-62. PubMed ID: 8862691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus.
    Laakso M
    J Diabetes Complications; 1997; 11(2):137-41. PubMed ID: 9101400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group.
    Steiner G
    Diabetologia; 1996 Dec; 39(12):1655-61. PubMed ID: 9081851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus.
    Laakso M
    Ann Med; 1996 Aug; 28(4):341-5. PubMed ID: 8862689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating lipid abnormalities in patients with type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2001 Dec; 88(12A):37N-40N. PubMed ID: 11788129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.
    Lancet; 2001 Mar; 357(9260):905-10. PubMed ID: 11289345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.
    Papadakis JA; Milionis HJ; Press M; Mikhailidis DP
    J Diabetes Complications; 2001; 15(4):211-26. PubMed ID: 11457674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of diabetic dyslipidemia.
    Garg A
    Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
    Koskinen P; Mänttäri M; Manninen V; Huttunen JK; Heinonen OP; Frick MH
    Diabetes Care; 1992 Jul; 15(7):820-5. PubMed ID: 1516498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipoproteinaemia in manifest diabetes.
    Manzato E; Crepaldi G
    J Intern Med Suppl; 1994; 736():27-31. PubMed ID: 7986305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients.
    Rönnemaa T; Laakso M; Kallio V; Pyörälä K; Marniemi J; Puukka P
    Am J Epidemiol; 1989 Oct; 130(4):632-45. PubMed ID: 2773912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprandial lipoproteins in non-insulin-dependent diabetes mellitus.
    Coppack SW
    Diabet Med; 1997 Aug; 14 Suppl 3():S67-74. PubMed ID: 9272617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.
    Uusitupa MI; Niskanen LK; Siitonen O; Voutilainen E; Pyörälä K
    Circulation; 1990 Jul; 82(1):27-36. PubMed ID: 2194696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of dyslipidemia in adults with diabetes.
    Haffner SM
    Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
    Vakkilainen J; Steiner G; Ansquer JC; Aubin F; Rattier S; Foucher C; Hamsten A; Taskinen MR;
    Circulation; 2003 Apr; 107(13):1733-7. PubMed ID: 12665498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.
    Sweany AE; Shapiro DR; Tate AC; Goldberg RB; Stein EA
    Clin Ther; 1995; 17(2):186-203. PubMed ID: 7614520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.